Stock · BAYN.DE · Healthcare
Germany · Large Cap · Revenue 12 mo. €45.4B
Price as of 11/06/2026
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. It has a commercial agreement with Neste to Jointly scale newgold winter canola for biofuels production. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Original text from the data provider
Summary
44.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €2.1B (2025), it supports €23.2B. The remaining €32.1B of the market value assume it grows 12.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.1%
no growth afterwards
Price to operating cash flow 13.1×, above its usual range.
Middle half of 20 quarters: 4.1× to 9.7×, median 6.8×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
No indication in the stored figures.
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
5 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | −13.95% | 11.52% | Rank 8 |
| Return on capital (Greenblatt) | 54.98% | 32.55% | Rank 73 |
| EBIT margin | 15.26% | 18.31% | Rank 41 |
| FCF margin | 4.57% | 14.12% | Rank 19 |
| Gross margin | 59.21% | 60.99% | Rank 47 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | −2.21% | 8.04% | Rank 5 |
| Earnings growth, 3 years per yeardoes not count towards the rank | – | 5.44% | |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 5.46% | 3.66% | Rank 69 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | −6.63% | 2.90% | Rank 1 |
| FCF yield | 3.77% | 3.63% | Rank 51 |
| EV/saleslower is better | 1.86 | 4.03 | Rank 81 |
| EV/EBITlower is better | 12.19 | 21.73 | Rank 87 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 100.05% | 8.66% | Rank 98 |
| Share price, 6 months | 50.78% | 24.27% | Rank 87 |
| Share price, 3 months | 16.72% | 15.42% | Rank 53 |
| Distance from 52-week high | −1.14% | −7.35% | Rank 82 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −5.94% | 0.30% | Rank 88 |
| Change in share countlower is better | 0.00% | 0.00% | Rank 45 |
| Dividend streak in years | 1 | 10 | Rank 29 |
| Price reaction to results, market-adjusted | −1.00% | 0.05% | Rank 36 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 23.46% | 48.40% | Rank 12 |
| Net debt/EBITDAlower is better | 11.17 | 1.11 | Rank 0 |
| Debt to equitylower is better | 1.44 | 0.48 | Rank 12 |
| Volatility, 1 yearlower is better | 43.18% | 31.42% | Rank 17 |
Ten years in figures
| Year | Revenue, €B | EBIT margin | FCF, €B | Shares | Net debt, €B |
|---|---|---|---|---|---|
| 2016 | 34.9 | 16.3% | 6.5 | 846M | 16.4 |
| 2017 | 35.0 | 16.8% | 5.8 | 886M | 5.6 |
| 2018 | 36.7 | 3.8% | 5.3 | 941M | 36.6 |
| 2019 | 43.5 | 12.0% | 5.6 | 982M | 35.7 |
| 2020 | 41.4 | 0.0% | 2.5 | 982M | 37.4 |
| 2021 | 44.1 | 18.0% | 2.5 | 982M | 35.0 |
| 2022 | 50.7 | 16.2% | 4.1 | 982M | 36.5 |
| 2023 | 47.6 | 17.7% | 2.4 | 982M | 38.9 |
| 2024 | 46.6 | 9.6% | 4.6 | 982M | 34.6 |
| 2025 | 45.6 | 15.3% | 2.1 | 982M | 30.8 |
3 of 7 StockScorer Score rules met · How the score is built
Bayer AG mainly meets criteria in the Valuation category. Result from 18 strategies checked.
Bayer AG is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Bayer AG.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | −26.1 | 30.0 |
| P/B ratio | 2.1 | 4.8 |
| Return on equity (ROE) | −14.0% | 11.5% |
| Equity ratio | 23.5% | 48.4% |
| Debt-to-equity (D/E) | 1.44 | 0.48 |
| Dividend yield | 0.2% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BAYN.DE | Bayer AGthis page | |
| 4519.T | Chugai Pharmaceutical Co. Ltd. | locked |
| 4578.T | Otsuka Holdings Ltd | locked |
| BIIB | Biogen Inc | Low4.5 |
| 4568.T | Daiichi Sankyo Co. Ltd. | locked |
| 4503.T | Astellas Pharma Inc. | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.